The stock has more than 1800 trades and is currently trading at .62 The company’s highest trading volume day this year was less than 10 million, with a 52-week high of $2.50.
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
SOUTH SAN FRANCISCO, Calif., July 5, 2022 /PRNewswire/ — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder (“OUD”).